Orders from 100 GBP Free delivery from 205 GBP Ready for pickup dead drop: collect in 5 min

Substances · Lysergamides

ETH-LAD

C21H27N3O CAS 65527-61-9 Analytical reference material — not for human consumption
Preferred name
ETH-LAD
IUPAC name
(6aR,9R)-N,N,7-triethyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
Parent CAS number (reference)
65527-61-9
Molecular formula
C21H27N3O
Molecular weight
337.5 g/mol
InChIKey
MYNOUXJLOHVSMQ-DNVCBOLYSA-N
PubChem
CID 44457783
Source
PubChem
Verified synonyms & catalog abbreviations
6-Ethyl-6-nor-LSD ETHLAD ETH LAD

Matching Listings in This Store's Catalog

Verified Neurochemical & Toxicological Intelligence

ETH-LAD

Potent N6-Ethyl Lysergamide (5-HT2A Partial Agonist) Lysergamide
Verified PubChem & CAS Identity C21H27N3O · CAS 65527-61-9 · CID 44457783
Calibrated Physical Form Dissolved Liquid Solution (µg Calibrated)
≥98% Analytical Purity Verified 337.5 g/mol
Peer-Reviewed & Agency Citations 2 · verified sources

Receptor Telemetry & Mechanism of Action

5-HT₂ₐ Perceptual & Visual Signaling Partial Agonist
5-HT₁ₐ / 5-HT₂c Serotonergic Modulation Active
D₂ / Adrenergic Dopaminergic / Somatic Tone Moderate

Direct N6-ethyl-nor-LSD agonist showing slightly higher in vitro 5-HT2A affinity than LSD-25 itself.

Biotransformation & Active Metabolites

Directly active without conversion to LSD-25.

Temporal Pharmacokinetics

Potent N6-Ethyl Lysergamide (5-HT2A Partial Agonist) — Supplied as dissolved liquid solution; ~20–30% steeper per microgram than 1P-LSD/1cP-LSD with pronounced visual density and early somatic thermoregulation/nausea sensitivity above 120 ug.

  1. Onset 30–75 min
  2. Peak Window 2–4 h
  3. Total Window 8–12 h
  4. Residual / Half-Life 4–8 h residual

Supplied as dissolved liquid solution; ~20–30% steeper per microgram than 1P-LSD/1cP-LSD with pronounced visual density and early somatic thermoregulation/nausea sensitivity above 120 ug.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
15–20 ug
Cognitive & Sensory

Subtle threshold receptor activity (Potent N6-Ethyl Lysergamide (5-HT2A Partial Agonist)).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
20–60 ug
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
60–120 ug
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
120–200 ug
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
200+ ug
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

Lithium salts

Strongly documented to provoke acute tonic-clonic seizures, fugue states, and severe psychotic episodes with lysergamides.

Tramadol

Lowers seizure threshold alongside 5-HT2A excitation.

Elevated Hazard — Avoid

Cannabis & Strong Stimulants (Cathinones, Amphetamines, Cocaine)

Exponentially amplifies thought loops, tachycardia, anxiety, and acute paranoia.

Caution / Receptor Attenuation

SSRIs / SNRIs & Benzodiazepines

Chronic SSRIs and acute benzodiazepines markedly attenuate 5-HT2A perceptual effects.

Structural Isomer & Sibling Comparison

Supplied as dissolved liquid solution; ~20–30% steeper per microgram than 1P-LSD/1cP-LSD with pronounced visual density and early somatic thermoregulation/nausea sensitivity above 120 ug.

Physicochemical Stability & Storage

Form: Clear, colorless calibrated liquid solution for microgram (µg) volumetric measurement. · Supplied pre-dissolved in analytical carrier; sensitive to chlorine/tap water.

Highly sensitive to UV light, heat, and chlorine; store airtight in amber glass under cold/refrigerated conditions.

Cross-Tolerance & Dependence Profile

Immediate rapid 5-HT2A receptor downregulation within hours, cross-tolerant with all tryptamines and phenethylamines; baseline sensitivity typically resets over 10–14 days. Non-addictive physiologically.

Comprehensive Analytical & Toxicological Monograph

ETH-LAD ((6aR,9R)-N,N,7-triethyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide; CAS 65527-61-9, PubChem CID 44457783) is a lysergamide reference compound (C21H27N3O, 337.5 g/mol) classified pharmacologically as a Potent N6-Ethyl Lysergamide (5-HT2A Partial Agonist). Direct N6-ethyl-nor-LSD agonist showing slightly higher in vitro 5-HT2A affinity than LSD-25 itself. Directly active without conversion to LSD-25. In published observational and toxicological literature, threshold response is noted at 15–20 ug, light range at 20–60 ug, common reference range at 60–120 ug, strong intensity at 120–200 ug, and heavy/adverse territory at 200+ ug, with an onset of 30–75 min, peak window of 2–4 h, and total duration of 8–12 h (4–8 h residual). Supplied as dissolved liquid solution; ~20–30% steeper per microgram than 1P-LSD/1cP-LSD with pronounced visual density and early somatic thermoregulation/nausea sensitivity above 120 ug. Critical contraindications include Lithium salts, Tramadol.

Chemical Architecture & Structural Profile

ETH-LAD ((6aR,9R)-N,N,7-triethyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide) is a reference compound belonging to the Lysergamides class, characterized by the molecular formula C21H27N3O and a molar mass of 337.5 g/mol. The parent molecule is indexed under CAS registry number 65527-61-9 and in the NCBI PubChem database as CID 44457783 (Standard InChIKey: MYNOUXJLOHVSMQ-DNVCBOLYSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), ETH-LAD is indexed within the Lysergamides structural group. Toxicological notes (PsychonautWiki): toxic dose is unknown. Dependence liability (PsychonautWiki): not habit-forming. Documented cross-tolerance class: psychedelic. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations

Documented Contraindications & Interactions

High-risk / Dangerous combinations

Unsafe combinations (elevated hazard)

Uncertain combinations (caution advised)